Founded December 2025 in Dallas-Fort Worth. Built by healthcare industry insiders who understand denial logic from the inside — not from the outside looking in.
Existing RCM tools flag errors after the fact. They tell you what was denied but not why — and not how to win the appeal. There's no clinical reasoning, no mechanistic explanation, no evidence generation. Just another alert to action manually.
Generic LLMs don't know that Palmetto GBA's LCD L38016 requires specific frequency justification language, or that Z-Codes must precede MolDX test submissions, or that a CYP2D6 ultrarapid metabolizer makes a negative opiate screen clinically expected. We do.
Waystar serves hospital systems. SmarterDx targets large health systems. XiFin focuses on billing middleware. Nobody is building AI-native clinical reasoning for independent toxicology and molecular labs. That's our market, and it's defensible.
Our engine reads clinical documentation and reasons through it against payer-specific LCD criteria — the same cognitive process a medical director performs when reviewing an appeal. We generate the mechanistic "why" behind every recovery argument, not a template letter.
Our founder led software engineering inside Cigna and built systems across UnitedHealth Group, Optum and Teladoc; co-founder Manasa spent 10+ years across UnitedHealth Group, Interwell Health and ECFMG. We've engineered within the payer systems that decide coverage and generate denials — so we know the adjudication logic from the inside, and exactly what evidence reverses it.
We're so confident in our outcomes that we align our entire pricing model around them. 15-20% of recovered revenue only. Zero upfront. Zero implementation fees. If you don't recover, we don't get paid. That's how sure we are that we'll win.
Two founders who engineered and operated inside the payer systems Ardia is built to navigate — with a CEO driving strategy, partnerships, and growth.
A practicing veterinary doctor since 2010–11, Paramesh leads business strategy, go-to-market, partnerships, and investor relations — bringing a clinical and scientific lens to Ardia's governed, non-diagnostic AI.
10+ years across UnitedHealth Group, Interwell Health, and ECFMG — inside the payer and health-services operations that decide coverage and manage care. She grounds Ardia's product direction and go-to-market in real-world workflows.
Creator of the TARA reasoning framework. 15+ years in enterprise IT with direct healthcare-engineering roles — Software Engineering Lead at Cigna, Senior SDE at Teladoc, Senior Software Developer at ECFMG, and UnitedHealth Group — building inside the payer systems that generate denials.
Independent labs and specialty practices have been sold generic RCM tools, hospital-focused CDI, or rules-based clearinghouses. None were built for the specific denial logic, MAC rules, and clinical evidence requirements of toxicology and molecular diagnostics.
| Capability | ✦ ARDIA PRECISION HEALTH Purpose-built for independent labs |
XiFin RCM | SmarterDx | Waystar | Change Healthcare |
|---|---|---|---|---|---|
Toxicology Lab Focus Purpose-built tox CPT logic, MAC routing, UDS protocol intelligence |
Purpose-built · 80+ Panel
Full G0480–G0659 coverage, UDS presumptive/confirmatory logic, treatment center workflows, 24–72hr TAT support
Why it matters: Every toxicology denial requires knowledge of the specific CPT code, MAC LCD (L35006 etc.), and the clinical rationale for the test order. Generic RCM tools flag — Ardia resolves.
| Generic billing only | Add-on labs module | Not applicable | Not applicable |
Clinical AI Reasoning Engine Autonomous appeal narrative — not rules triggers, not templates |
Core Differentiator
Generates clinical-grade appeal narratives citing NCCN, ASCO, CPIC, AHA guidelines. Trained on MAC LCD logic. Designed to cite a verifiable source for each clinical claim, for licensed-practitioner review.
Why it matters: Denials are won with clinical evidence arguments, not billing corrections. SmarterDx does CDI for hospitals. Waystar fires rules. Neither argues clinical necessity the way a physician would — Ardia does.
| Rules-based only | Hospital CDI only | Rule triggers only | No AI reasoning |
MolDX / Z-Code Intelligence NGS/PGx local coverage determination routing for all 7 MACs |
Full Module · All 7 MACs
Automated Z-code routing, MolDX registry lookup, MAC-specific LCD cross-reference (CGS J-15, Palmetto J-M, WPS J-5/J-8, etc.). Pre-submission validation.
Why it matters: MolDX manages ~70% of all molecular diagnostic claims. Getting a NGS claim paid requires knowing the exact MAC, the Z-code, the LCD, and the supporting clinical evidence. Only Ardia handles this end-to-end.
| Partial coverage | Not applicable | Not applicable | Not applicable |
Pharmacogenomics (PGx) CYP2D6, CYP2C19, SLCO1B1, TPMT, DPYD appeal intelligence |
Included · 40+ Genes
CPIC guideline citations, failed medication trial documentation, prior authorization intelligence for all major PGx panels. CO-55 reversal strategy built-in.
Why it matters: PGx denials are overwhelmingly CO-55 (experimental). Reversing them requires citing CPIC Level A evidence plus documenting the failed antidepressant/statin trial. Ardia does this in seconds.
| Not included | Not applicable | Not applicable | Not applicable |
PAMA 2027 Rate Defense Data collection automation, rate impact modeling, efficiency gap analysis |
Built-in · Jan 2027 Cliff
Automated PAMA data collection (May 1–Jul 31 2026 window), rate impact projection per CPT code, cost-to-collect reduction to stay above new CLFS floor.
Why it matters: Labs that fail to submit PAMA data by Jul 31, 2026 face the full rate cliff Jan 1, 2027. Labs that do submit need to know which tests become economically unviable. Only Ardia models both.
| Manual tracking only | Not applicable | Limited analytics | Not applicable |
Texas SB 1188 Compliance Human-in-loop review, US data residency, AI disclosure native |
Native · Audit Trail Built-in
Every AI output requires practitioner review before action. Full immutable audit log. All data stored in US infrastructure. Patient-facing AI disclosure built in.
Why it matters: Texas SB 1188 (Sep 1, 2025) and TRAIGA (Jan 1, 2026) impose $250K penalties for non-compliant AI clinical tools. Ardia was designed to be compliant from day one — competitors retrofitted nothing.
| Not addressed | Not addressed | Not addressed | Not addressed |
Contingency Pricing Zero upfront cost — provider pays only % of actual recovery |
15–20% of Recovery
No subscription fees for early customers. No setup cost. No IT integration required for Phase 1. Providers pay only when Ardia successfully recovers a denied claim.
Why it matters: Independent labs cannot afford $50–150K/year SaaS subscriptions on top of thin margins. Contingency pricing eliminates all financial risk for the customer and aligns Ardia's incentives perfectly.
| Per-claim fees | Subscription SaaS | Subscription SaaS | Subscription SaaS |
Sales Cycle (Ind. Labs) Time from first contact to live production |
2–8 Weeks
No EHR integration required for Phase 1 — upload CSV or paste HL7 835. Lab director can go from zero to first denial analysis in minutes, not a months-long procurement cycle. PLG model eliminates procurement bottleneck.
Why it matters: Healthcare enterprise sales average 12–18 months. Ardia's product-led approach means a lab director can experience value before involving IT, legal, or procurement — compressing the cycle 10×.
| 6–18 months | 6–12 months | 6–18 months | 3–9 months |
Independent Lab Target Market Who the product is optimized for |
Built for Indep. Labs
Toxicology labs, molecular diagnostic labs, specialty practices, MAT/OTP clinics, pulmonary & respiratory practices. The exact customer segment every enterprise vendor ignores.
Why it matters: Enterprise RCM vendors (XiFin, Waystar, Change Healthcare) target hospital systems and large reference labs. Independent labs — 7,000+ in the US — are underserved, undertooled, and overly denied.
| Enterprise labs only | Hospital systems | All sizes, generic | Large systems |
Pulmonary & Respiratory RCM PFT, sleep-study & respiratory-panel denial recovery |
PulmoIQ™ Module
Applies clinical AI reasoning to pulmonary and respiratory claims — pulmonary function tests, sleep studies, and respiratory pathogen panels — anchoring each appeal to the applicable clinical-necessity evidence and MAC coverage policy.
Why it matters: Pulmonary and respiratory tests are frequently denied for documentation and medical-necessity gaps. PulmoIQ™ is built to argue clinical necessity for exactly these specialty claims, where generic RCM tools carry no coverage logic.
| Not applicable | Not applicable | Basic analytics only | Not applicable |
Upgrade-Ready Architecture QAOA/VQE appeal optimization · NIST PQC migration roadmap |
Phase 4 · 2032+
Quantum Approximate Optimization Algorithm for denial queue sequencing. Post-quantum cryptography migration plan per NIST 2024 standards. QUBO formulation for batch processing.
Why it matters: Quantum optimization for claims workflows is a speculative, long-range research interest — not a capability we claim today. Ardia's Phase 4 roadmap simply keeps the architecture open to explore these methods if and as the field matures.
| No roadmap | No roadmap | No roadmap | No roadmap |
No competitor was purpose-built for independent toxicology labs, molecular diagnostics, and pulmonary specialty practices. XiFin handles billing. SmarterDx does hospital CDI. Waystar is a clearinghouse. Ardia is the only platform that applies clinical AI reasoning specifically to the denial codes, MAC LCDs, and evidence standards that govern independent lab reimbursement.
From DFW toxicology MVP to multi-specialty global precision medicine infrastructure — explore the full roadmap.
View Full Roadmap →